Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

- ORACLE MS Phase III Trial Will Assess Effectiveness of Cladribine Tablets in Preventing Conversion to Definite Multiple Sclerosis in Addition to the

Fully Enrolled Phase III Pivotal Trial -

- the CLARITY Study -

- for Treatment of Relapsing Forms of Multiple Sclerosis

GENEVA, Sept. 18 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the initiation of a Phase III trial to evaluate the therapeutic effects of its proprietary oral formulation of Cladribine (Cladribine tablets) in patients at risk of developing multiple sclerosis (MS).

The trial, called ORACLE MS (Oral Cladribine in Early MS) will evaluate the safety and efficacy of two dosage regimens of Cladribine tablets versus placebo in the treatment of patients who have experienced a first clinical event suggestive of MS. Cladribine tablets are currently also being evaluated in a fully enrolled Phase III pivotal trial - the CLARITY(1) study -- for treatment of relapsing forms of MS. As announced in January 2007, CLARITY was the first pivotal trial among all Phase III oral compounds in development for MS to complete enrollment. Cladribine tablets have been granted a fast track designation by the US Food and Drug Administration.

"There is increasing evidence supporting the initiation of treatment with a disease-modifying drug in patients who have experienced a first clinical event suggestive of multiple sclerosis, an initial stage of the disease when clinical manifestations are not necessarily pronounced but where the potential exists for irreversible neurological damage to take place," said Dr. Thomas Leist, Associate Professor of Neurology and Director of the Comprehensive MS Center at Thomas Jefferson University, Philadelphia, PA, and an investigator in the ORACLE MS study. "The ORACLE MS study will evaluate the effectiveness and safety of Cladribine tablets in preventing conversion to
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... CHICAGO , Sept. 23, 2014  Hill-Rom (NYSE: ... agreement with Providence Health ( Renton, WA ... new agreement expands the companies, existing relationship as Hill-Rom ... Maternal, and Bariatric capital bed frame and surface products. ... largest health systems in the U.S.  It operates 34 ...
(Date:9/23/2014)... , Sept. 23, 2014 Research ... "Biopharmaceutical and Vaccine Production Markets" report to ... many new therapies and vaccines - including products to ... are still huge challenges during the final stages of ... when and how to risk production capital to upscale ...
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3
... 10th Annual Superbugs and Superdrugs Conference on ... ... 10 Enanta Pharmaceuticals, a,leader in the development of small ... program to,evaluate a new macrolide-related drug class, Bicyclolides, in the ...
... - Strategic Collaboration with the National Cancer Institute,s NABTT ... ... 10 BiPar Sciences, Inc. today,announced the expansion of the clinical ... the most,common glioma in adults. BSI-201, the first poly ADP-ribose polymerase,(PARP) ...
Cached Medicine Technology:Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer 2
(Date:9/23/2014)... Swedish study shows that adolescents who suffer from sleep ... to succeed academically compared to those who enjoy a ... in the journal Sleep Medicine . , In ... between 12 and 19 from Uppsala County, researchers from ... habitual short sleep duration (less than 7 hours per ...
(Date:9/23/2014)... San Jose, California (PRWEB) September 23, 2014 ... – Medical transcription is the process of translating ... assessment, clinical course, therapeutic procedures, and prognosis, into ... health insurance agents, patients, and healthcare providers. With ... documentation of each patient’s condition, outsourcing of such ...
(Date:9/23/2014)... If you or a loved one ... treatment may be a challenge. Fortunately, an inventor from ... is designed to improve the experience. , He developed ... having to remove, tear or reposition their clothing. Furthermore, ... their dignity. At the same time, it safeguards their ...
(Date:9/23/2014)... be able to grow enough food there to maintain ... food in NASA,s Orion spacecraft on the year-long trip ... extreme conditions? These are questions scientists are trying to ... International Space Station (ISS). , Plant biology investigations called ... to adapt to a microgravity environment. When a crew ...
(Date:9/23/2014)... allow electrical signals to pass unhindered through new ... Texas Children,s Hospital. , A team led by ... Matteo Pasquali created the patches infused with conductive ... a sponge-like bioscaffold that contains microscopic pores and ... overcome a limitation of current patches in which ...
Breaking Medicine News(10 mins):Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 2Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 3Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Getting to the root of the problem in space 2Health News:Getting to the root of the problem in space 3Health News:Getting to the root of the problem in space 4Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3
... revolutionary EnviroCool fresh air cooling system also ... air pollution, WINCHESTER, Calif., June 11 With ... on the rise, homeowners around the,country are turning to ... cool their homes: QuietCool and EnviroCool., The QuietCool ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it will ... held June 24-26, 2008 in New York,City., Walter ... Corp.,will present on Tuesday, June 24th at 10:15 am ... presentation can be accessed through,our website at http://www.hmsholdings.com/news/presentations.asp ...
... Research Group, offering hope to sufferers of asbestos-related ... today. , Special guest Karen Banton, widow of ... the group, saying: , "Today brings hope of ... asbestos exposure and ultimately a future free of ...
... Award Presented to QualityMetric Employee at Annual ... ... 11 In recognition of clinical,research to improve the understanding ... Senior Scientist with,QualityMetric(TM) Health Outcomes Solutions, was presented the 2008-2009,American ...
... Patient Share by 2012, According to a ... New Report from Decision Resources, ... the,world,s leading research and advisory firms focusing on pharmaceutical and,healthcare ... of,fistulas in a greater percentage of patients than,Centocor/Schering-Plough/Mitsubishi Tanabe,s Remicade ...
... in children may have an impact on cardiovascular functioning ... according to a research abstract that will be presented ... the Associated Professional Sleep Societies (APSS). , The study, ... of Melbourne and Monash University, Melbourne, Victoria, Australia, focused ...
Cached Medicine News:Health News:A Far Less Expensive, Green Alternative to Traditional Air Conditioning, from QuietCool 2Health News:New research group offers hope to asbestosis sufferers 2Health News:New research group offers hope to asbestosis sufferers 3Health News:QualityMetric Senior Scientist Min Yang, MD, PhD, Recipient of Prestigious Clinical Research Award in Women's Health 2Health News:QualityMetric Senior Scientist Min Yang, MD, PhD, Recipient of Prestigious Clinical Research Award in Women's Health 3Health News:A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market 2Health News:Primary snoring in children impacts cardiovascular functioning 2Health News:Primary snoring in children impacts cardiovascular functioning 3
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
Thermal Cautery, Sterile Single-Use Units for Vasectomy. Burns at approximately 1200C (2200 F). Integrated unit includes handle, vasectomy tip, & AA batteries. Box of 10 units. Discounts on 2 or more...
Non-Cantilevered Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring diameter approximately 3.0 mm....
... earmolds add comfort and enhance hearing abilities ... paramedics, Flight-for-Life helicopter personnel, emergency technicians and ... specific in design and can be fabricated ... in today's industry to ensure clear sound ...
Medicine Products: